Xencor, Inc.

What they do

Xencor designs engineered Fc domains and multi-specific antibody formats, including CD3 T-cell engaging bispecifics, CD28 co-stimulatory bispecifics, and the TL1A x IL23p19 bispecific XmAb412. It advances wholly owned candidates into Phase 1 and Phase 2 studies and partners other programs to access development and commercialization capabilities. Three marketed medicines have been developed with its XmAb technologies. Wholly owned clinical programs include XmAb819 (ENPP3 x CD3), XmAb541 (CLDN6 x CD3), XmAb808 (B7-H3 x CD28), XmAb942, and plamotamab and XmAb657 in autoimmune disease.

Revenue drivers

• Collaboration and milestone revenue —
• Wholly owned clinical pipeline —
• XmAb technology licensing —

Recent performance

Second quarter 2026 revenue was $51.2M versus $4.5M in the first quarter of 2026 and $28.2M in the fourth quarter of 2025. Full year 2025 revenue was $125.6M with a net loss of $91.9M, compared with a $232.6M net loss on $110.5M of revenue in 2024. Operating cash flow was negative $135.1M in 2025, an improvement from negative $202.2M in 2024. At June 30, 2026, cash and equivalents were $44.7M, total assets were $725.0M, total liabilities were $221.7M, long-term debt was $77.5M and shareholder equity was $503.2M.

Strategy

Management is prioritizing clinical execution and data delivery, with seven clinical studies currently enrolling. Xencor has prioritized the XmAb541 and XmAb808 combination in CLDN6-expressing tumors while XmAb541 monotherapy expansion cohorts in high-grade serous ovarian carcinoma and germ cell tumors complete enrollment by year end. XmAb819 is on track for a registration-enabling monotherapy study in advanced ccRCC during 2027, with the first XenLock bispecific XmAb412 now in a healthy participant Phase 1 study. The company states that prioritization of the XmAb541/XmAb808 combination is expected to reduce projected overall XmAb541 program expense for 2027 and 2028, and it continues to advance, partner or discontinue programs based on data.

Risks

• No approved products and continuing losses — Xencor is clinical-stage with no commercial revenue of its own, has incurred significant losses since inception, and expects to continue incurring significant losses for the foreseeable future.
• Need for additional financing — The company states it will require additional financing and may be unable to raise sufficient capital, which could force it to delay, reduce or abandon research and development programs.
• Clinical data may change — Preliminary, interim and topline data announced or published may change as more patient data become available and could result in material changes in the final data, as seen with XmAb541 monotherapy activity of approximately 14% ORR in ovarian cancer and 28% ORR in germ cell tumors.
• Internal control weakness and restatement — The company has disclosed a failure to maintain effective internal controls that led to the restatement of its financial statements, and has flagged the risk that it may experience additional material weaknesses.

Outlook

Management points to an accelerating tempo of readouts in 2027 and beyond. XmAb819 Phase 1 results in advanced ccRCC were accepted for a proffered paper oral presentation at ESMO 2026 (October 23-27, Madrid), a registration-enabling monotherapy study in advanced ccRCC is on track for 2027, and a sub-study in intermediate- or poor-risk ccRCC after IO doublet therapy is planned to open in the third quarter of 2026. XmAb942 enrollment in the XENITH-UC study remains on track with the 12-week induction primary endpoint expected in the second half of 2027, and healthy participant data for XmAb412 are planned for the first half of 2027.